Ticker

No recent analyst price targets found for GCTK.

Latest News for GCTK

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor in the strategic business combination between Glucotrack, Inc. (Nasdaq: GCTK) and Lōkahi Therapeutics, and as exclusive placement agent for a concurrent convertible note financing of approximately $5.7 million to support…

GlobeNewsWire • Jul 17, 2026
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives

RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi"), a clinical-stage biopharmaceutical company advancing innovative non-opioid biologic therapies and applying its proprietary ai²™ methodology to identify and develop high-value healthcare opportunities, today announced…

GlobeNewsWire • Jul 17, 2026
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and…

GlobeNewsWire • Jul 16, 2026
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and…

GlobeNewsWire • Jul 14, 2026
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled “Methods and Systems for Continuously…

GlobeNewsWire • Jul 8, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for GCTK.

No House trades found for GCTK.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top